CPRX | Catalyst Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	23.52 - 24.50
52 Week Range	14.47 - 26.16
Beta	0.63
Implied Volatility	42.34%
IV Rank	85.17%
Day's Volume	1,297,125
Average Volume	1,351,389
Shares Outstanding	121,450,000
Market Cap	2,945,162,500
Sector	Healthcare
Industry	Biotechnology
IPO Date	2006-11-08

Valuation
Profitability
Growth
Health
P/E Ratio	18.51
Forward P/E Ratio	14.81
EPS	1.31
1YR Price Target	12.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	167
Country	USA
Website	CPRX

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

CPRX's peers: DAWN, TERN, XFOR, INZY, MREO, EXEL, TGTX, VKTX, MDGL, BTAI, AXSM, INCY, IMGN, SRPT, ACAD, ICPT, HEPA, AKRO, RETA

*Chart delayed

Analyzing fundamentals for CPRX we got that it has strong fundamentals where Valuation is considered to be undervalued, Profitability is stunning wealthy, Growth is exceptionally good and Health is very strong. For more detailed analysis please see CPRX Fundamentals page.

Watching at CPRX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on CPRX Technicals page.